Objective: to explore the clinical treatment of critically ill MDS and elderly patients with acute myeloid leukemia in the formulation of treatment plan, azacytidine, low-dose cytarabine combined intervention measures...Objective: to explore the clinical treatment of critically ill MDS and elderly patients with acute myeloid leukemia in the formulation of treatment plan, azacytidine, low-dose cytarabine combined intervention measures on the treatment effect. Methods: 25 cases of critically ill MDS and elderly patients with acute myeloid leukemia in our hospital were selected and analyzed. The research time span was from May 2018 to October 2019. The patients were randomly divided into control group and observation group. There were 12 patients in the control group and 13 patients in the observation group. The patients in the control group were treated with azacytidine and the observation group were treated with azacytidine and low-dose cytarabine. The clinical effects of different treatment schemes were compared by comparing the effect of disease control of patients in groups. Results: after the completion of the course of treatment, the improvement degree of the observation group was better than that of the control group, and the total effective rate of the observation group was higher than that of the control group, and the difference between the two groups was statistically significant (P < 0.05). Conclusion: the combination of azacytidine and low-dose cytarabine in the treatment of critically ill MDS and elderly patients with acute myeloid leukemia has a satisfactory intervention effect on the condition of the disease and ensures the comfortable experience of the patients during the treatment, which is worthy of vigorous use in clinical practice and worthy of praise.展开更多
文摘Objective: to explore the clinical treatment of critically ill MDS and elderly patients with acute myeloid leukemia in the formulation of treatment plan, azacytidine, low-dose cytarabine combined intervention measures on the treatment effect. Methods: 25 cases of critically ill MDS and elderly patients with acute myeloid leukemia in our hospital were selected and analyzed. The research time span was from May 2018 to October 2019. The patients were randomly divided into control group and observation group. There were 12 patients in the control group and 13 patients in the observation group. The patients in the control group were treated with azacytidine and the observation group were treated with azacytidine and low-dose cytarabine. The clinical effects of different treatment schemes were compared by comparing the effect of disease control of patients in groups. Results: after the completion of the course of treatment, the improvement degree of the observation group was better than that of the control group, and the total effective rate of the observation group was higher than that of the control group, and the difference between the two groups was statistically significant (P < 0.05). Conclusion: the combination of azacytidine and low-dose cytarabine in the treatment of critically ill MDS and elderly patients with acute myeloid leukemia has a satisfactory intervention effect on the condition of the disease and ensures the comfortable experience of the patients during the treatment, which is worthy of vigorous use in clinical practice and worthy of praise.
